GlassScriptPhysician profile
Gretchen Reichmann
NPI 1306215975
$13,016.94
in general payments reported to CMS, 2019-2025
53 companies · $3,848 in 2025
The $3,848 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $559 · 2022: $2,541 · 2023: $3,154 · 2024: $2,915 · 2025: $3,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,883 · Travel and Lodging: $33.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,882.91 |
| Travel and Lodging | $33.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,734.89 | 2022-2025 | |
| Lundbeck LLC | $1,115.46 | 2022-2025 | Vyepti |
| Ucb, INC. | $1,063.46 | 2023-2025 | Briviact, Nayzilam, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $728.16 | 2021-2025 | Austedo Xr, Ajovy, Austedo |
| Boston Scientific Corporation | $697.32 | 2021-2025 | Wavewriter Alpha Prime 16, Artisan |
| Averitas Pharma INC. | $657.87 | 2023-2025 | Qutenza |
| Amgen INC. | $570.31 | 2021-2025 | Uplizna, Aimovig |
| Collegium Pharmaceutical, INC. | $538.94 | 2022-2025 | Xtampza, Belbuca |
| Pfizer INC. | $485.69 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $386.38 | 2022-2023 | Trudhesa |
| Neurocrine Biosciences, INC. | $355.02 | 2023-2025 | Ongentys, Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $327.41 | 2022 | |
| Saluda Medical Americas, INC. | $302.42 | 2025 | Evoke |
| Genzyme Corporation | $265.78 | 2021-2023 | |
| Lilly USA, LLC | $234.14 | 2022-2025 | Emgality, Amyvid, Kisunla |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gretchen Reichmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.